Log in
Enquire now
‌

US Patent 11359021 PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11359021
Patent Inventor Names
Xiaoling Gu0
Lei Zhang0
Jinming Gu0
Qiyue Hu0
Jiahua Jiang0
Weikang Tao0
Date of Patent
June 14, 2022
Patent Application Number
16960297
Date Filed
January 9, 2019
Patent Citations
‌
US Patent 10815304 PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
0
Patent Citations Received
‌
US Patent 11780923 PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
Patent Primary Examiner
‌
Laura B Goddard

A novel PD-L1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. A humanized antibody comprising a CDR of the PD-L1 antibody, a pharmaceutical composition comprising the PD-L1 antibody and the antigen-binding fragment thereof and a use of the PD-L1 antibody as a drug. A use of a humanized PD-L1 antibody in preparing a drug for treating diseases or disorders associated with PD-L1.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11359021 PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.